Epidemiology of moderate-to-severe psoriasis: a comparison between psoriasis patients treated with biological agents, conventional systemic drugs and topical agents

References

• Smith HC, Barker JN. Psoriasis and its management. BMJ. 2006;333:380–384.
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons P, Griffiths CE, et al. Global epidemiology of psoriasis: a systemic review of incidence and prevalence. J Invest Dermatol . 2013;133:377–385.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Fleischer AB, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol. 1997;37:564–569.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Tian H, Gilloteau I, et al. Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database. BMC Health Serv Res. 2017;17:337.
   PubMed Web of Science ®Google Scholar
• Dubertret L, Sterry W, Bos JD, et al.; CLEAR Multinational Study Group. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderateto-severe plaque psoriasis: Results from a phase III international randomized, placebo-controlled trial. Br J Dermatol. 2006;155:170–181.
   PubMed Web of Science ®Google Scholar
• Nast A, Gisondi P, Ormerod A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris-Update 2015-Short version-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29:2277–2294.
   PubMed Web of Science ®Google Scholar
• Nast A, Spuls P, Van Der Kraaij PG, et al. European S3-guideline on the systemic treatment of psoriasis vulgaris – update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017;31:1951–1963.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70:1914–1920.
   PubMed Web of Science ®Google Scholar
• Phan C, Sigal ML, Esteve E, et al.; GEM RESOPSO. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. 2016;30:78–82.
   PubMed Web of Science ®Google Scholar
• Grozdev IS, Van Voorhees AS, Gottlieb AB, et al.; National Psoriasis Foundation. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2011;65:537–545.
   PubMed Web of Science ®Google Scholar
• Ricceri F, Bardazzi F, Chiricozzi A, et al. Elderly psoriatic patients under biological therapies: an Italian experience. J Eur Acad Dermatol Venereol. 2019;33:143–146.
   PubMed Web of Science ®Google Scholar
• Colombo D, Cassano N, Bellia G, et al. Gender medicine and psoriasis. WJD. 2014;3:36–44.
   Google Scholar
• Hägg D, Sundström A, Eriksson M, et al. Severity of psoriasis differs between men and women: a study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register patients. Am J Clin Dermatol. 2017;18:583–590.
   PubMed Web of Science ®Google Scholar
• Hägg D, Eriksson M, Sundström A, et al. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. Plos One. 2013;8:e63619.
   PubMed Web of Science ®Google Scholar
• Carroll CL, Feldman SR, Camacho FT, et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151:895–897.
   PubMed Web of Science ®Google Scholar
• Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51:212–216.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol. 2007;57:81–83.
   PubMed Web of Science ®Google Scholar
• Evers AW, Kleinpenning MM, Smits T, et al. Treatment nonadherence and long-term effects of narrowband UV-B therapy in patients with psoriasis. Arch Dermatol. 2010;146:198–199.
   PubMedGoogle Scholar
• Lecha M, Mirada A, Lopez S, et al.; T.O.P. Research Group. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience. J Eur Acad Dermatol Venereol. 2005;19:414–417.
   PubMed Web of Science ®Google Scholar
• Lynde CW, Gupta AK, Guenther L, et al. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. J Dermatolog Treat. 2012;23:261–267.
   PubMed Web of Science ®Google Scholar
• Storm A, Andersen SE, Benfeldt E, et al. One in 3 prescriptions are never redeemed: primary non-adherence in an outpatient clinic. J Am Acad Dermatol. 2008;59:27–33.
   PubMed Web of Science ®Google Scholar
• Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140:408–414.
   PubMed Web of Science ®Google Scholar
• Gokdemir G, Ari S, Köşlü A. Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol. 2008;22:330–335.
   PubMed Web of Science ®Google Scholar
• Hercogová J, Ricceri F, Tripo L, et al. Psoriasis and body mass index. Dermatol Ther. 2010;23:152–154.
   PubMed Web of Science ®Google Scholar
• Duarte GV, Silva L. P d. Correlation between psoriasis’ severity and waist-to-height ratio. An Bras Dermatol. 2014;89:846–847.
   PubMed Web of Science ®Google Scholar
• Huang YH, Yang LC, Hui RY, et al. Relationships between obesity and the clinical severity of psoriasis in Taiwan. J Eur Acad Dermatol Venereol. 2010;24:1035–1039.
   PubMed Web of Science ®Google Scholar
• Sterry W, Strober BE, Menter A, International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157:649–655.
   PubMed Web of Science ®Google Scholar
• Grasgruber P, Hrazdíra E. Anthropometric characteristics of the young Czech population and their relationship to the national sports potential. JHSE. 2013;8:120–134.
   Google Scholar
• Na SJ, Jo SJ, Youn JL. Clinical study on psoriasis patients for past 30 years (1982-2012) in Seoul National University Hospital Psoriasis Clinic. J Dermatol. 2013;40:731–735.
   PubMed Web of Science ®Google Scholar
• García-Diez A, Ferrandiz Foraster C, Vanaclocha Sebastián F, et al. What characterizes the severity of psoriasis? Results from an epidemiological study of over 3,300 patients in the Iberian region Dermatology (Basel). 2008;216:137–151.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Madrange M, Viguier M, et al. Respiratory virus infection triggers acute psoriasis flares across different clinical subtypes and genetic backgrounds. Br J Dermatol. 2019;181:1304–1306.
   PubMed Web of Science ®Google Scholar
• Weisenseel P, Laumbacher B, Besgen P, et al. Streptococcal infection distinguishes different types of psoriasis. J Med Genet. 2002;39:767–768.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13:490–495.
   PubMed Web of Science ®Google Scholar
• Ceovic R, Mance M, Bukvic Mokos Z, et al. Psoriasis: female skin changes in various hormonal stages throughout life – puberty. Biomed Res Int. 2013;2013:571912.
   PubMed Web of Science ®Google Scholar
• Islam MT, Paul HK, Zakaria SM, et al. Epidemiological determinants of psoriasis. Mymensingh Med J. 2011;20:9–15.
   PubMedGoogle Scholar
• Murase JE, Chan KK, Garite TJ, et al. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol. 2005;141:601–606.
   PubMedGoogle Scholar
• Nelson PA, Barker Z, Griffiths CEM, et al.; IMPACT Team. ‘On the surface’: a qualitative study of GPs’ and patients’ perspectives on psoriasis. BMC Fam Pract. 2013;14:158–167.
   PubMed Web of Science ®Google Scholar
• Mattei PL, Corey KC, Kimball AB, et al. Cumulative life course impairment: evidence for psoriasis. In: Linder MD, Kimball AB, editros. Dermatological diseases and cumulative life course impairment. Current problems in dermatology. Basel: Karger; 2013. p. 82–90.
   Google Scholar
• Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63:40–46.
   PubMed Web of Science ®Google Scholar
• Wade AG, Crawford GM, Young D, et al. Severity and management of psoriasis within primary care. BMC Fam Pract. 2016;17:145.
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139:846–850.
   PubMed Web of Science ®Google Scholar
• Gupta MA, Schork NJ, Gupta AK, et al. Suicidal ideation in psoriasis. Int J Dermatol. 1993;32:188–190.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188.
   PubMed Web of Science ®Google Scholar
• Chiriac A, Podoleanu C, Azoicai D. Clinical and epidemiological factors predicting the severity of psoriasis. In: Chiriac A, editor. An interdisciplinary approach to psoriasis. IntechOpen; 2017. p. 123–162.
   Google Scholar
• Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163:586–592.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis. Arch Dermatol. 2007;143:1493–1499.
   PubMed Web of Science ®Google Scholar
• Gelfand J, Neimann A, Shin D, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–1741.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Targher G, Cagalli A, et al. Hyperuricemia in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;70:127–130.
   PubMed Web of Science ®Google Scholar
• Alpsoy S, Akyuz A, Erfan G, et al. Atherosclerosis, some serum inflammatory markers in psoriasis. Giornale Ital Dermatol Venereol. 2014;149:167–175.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Chen J, Zhou R, et al. The study of characteristics of hematological and biochemical parameters in patients with psoriasis and their values in its diagnosis and treatment. Int J Lab Med. 2013;34:1679–1681.
   Google Scholar
• Zhang D, Luo W, Wang J, et al. The level of detection and significance of serum uric acid in patients with psoriasis. J Practical Dermatol. 2012;5:132–134.
   Google Scholar
• Ibrahim SE, Helmi A, Yousef TM, et al. Association of asymptomatic hyperuricemia and endothelial dysfunction in psoriatic arthritis. Egypt Rheumatol. 2012;34:83–89.
   Google Scholar
• Isha Jain VK, Lal H. C-reactive protein and uric acid levels in patients with psoriasis Indian. J Clin Biochem. 2011;26:309–311.
   Google Scholar
• Severin E, Nave B, Stander M, et al. Total antioxidative capacity is normal in sera from psoriasis patients despite elevated bilirubin, tocopherol and urate levels. Dermatology (Basel). 1999;198:336–339.
   PubMed Web of Science ®Google Scholar
• Merola JF, Wu S, Han J, et al. Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann Rheum Dis. 2015;74:1495–1500.
   PubMed Web of Science ®Google Scholar
• Gui XY, Jin HZ, Wang ZJ, et al. Serum uric acid levels and hyperuricemia in patients with psoriasis: a hospital-based cross-sectional study. An Bras Dermatol. 2018;93:761–763.
   PubMed Web of Science ®Google Scholar
• Kwon HH, Kwon IH, Choi JW, et al. Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. Clin Exp Dermatol. 2011;36:473–478.
   PubMed Web of Science ®Google Scholar
• Eisen AZ, Seegmiller JE. Uric acid metabolism in psoriasis. J Clin Invest. 1961;40:1486–1494.
   PubMed Web of Science ®Google Scholar
• Baumann RR, Jillson OF. Hyperuricemia and psoriasis. J Invest Dermatol. 1961;36:105–107.
   PubMed Web of Science ®Google Scholar
• Tickner A, Mier PD. Serum cholesterol, uric acid and proteins in psoriasis. Br J Dermatol. 1960;72:132–137.
   PubMed Web of Science ®Google Scholar
• Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321–328.
   PubMed Web of Science ®Google Scholar
• Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829–835.
   PubMed Web of Science ®Google Scholar
• Murray ML, Bergstresser PR, Adams-Huet B, et al. Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. Clin Exp Dermatol. 2009;34:140–144.
   PubMed Web of Science ®Google Scholar
• Shiraishi H, Une H. The effect of the interaction between obesity and drinking on hyperuricemia in Japanese male office workers. J Epidemiol. 2009;19:12–16.
   PubMed Web of Science ®Google Scholar
• Li X, Miao X, Wang H, et al. Association of serum uric acid levels in psoriasis: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95:e3676.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:758–764.
   PubMed Web of Science ®Google Scholar
• Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:778–786.
   PubMed Web of Science ®Google Scholar
• Van der Voort EAM, Koehler EM, Dowlatshahi EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014;70:517–524.
   PubMed Web of Science ®Google Scholar
• Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity. JAMA Dermatol. 2013;149:1173.
   PubMed Web of Science ®Google Scholar
• Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol. 2012;53:190–197.
   PubMed Web of Science ®Google Scholar
• Narayanasamy K, Sanmarkan AD, Rajendran K, et al. Relationship between psoriasis and non-alcoholic fatty liver disease. Prz Gastroenterol. 2016;11:263–269.
   PubMed Web of Science ®Google Scholar
• Barak V, Selmi C, Schlesinger M, et al. Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J Autoimmun. 2009;33:178–182.
   PubMed Web of Science ®Google Scholar
• Harada K, Shimoda S, Sato Y, et al. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol. 2009;157:261–270.
   PubMed Web of Science ®Google Scholar
• Ogdie A, Grewal SK, Noe MH, et al. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study. J Invest Dermatol . 2018;138:760–767.
   PubMed Web of Science ®Google Scholar
• Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473–472.
   PubMed Web of Science ®Google Scholar